-
1
-
-
0037022204
-
Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: Primary results of the CHAMP study
-
DOI 10.1161/hc0502.103329
-
Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105:557-563. (Pubitemid 34123428)
-
(2002)
Circulation
, vol.105
, Issue.5
, pp. 557-563
-
-
Fiore, L.D.1
Ezekowitz, M.D.2
Brophy, M.T.3
Lu, D.4
Sacco, J.5
Peduzzi, P.6
-
2
-
-
45349084183
-
Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: Observations from the CRUSADE quality improvement initiative
-
DOI 10.1093/eurheartj/ehn126
-
Wang TY, Chen AY, Peterson ED, Becker RC, GiblerWB, Ohman EM, Roe MT. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. Eur Heart J 2008; 29:1103-1109. (Pubitemid 351844888)
-
(2008)
European Heart Journal
, vol.29
, Issue.9
, pp. 1103-1109
-
-
Wang, T.Y.1
Chen, A.Y.2
Peterson, E.D.3
Becker, R.C.4
Gibler, W.B.5
Ohman, E.M.6
Roe, M.T.7
-
3
-
-
84856046638
-
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE)
-
Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, et al. The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Can J Cardiol 2012; 28:48-53.
-
(2012)
Can J Cardiol
, vol.28
, pp. 48-53
-
-
Amad, H.1
Yan, A.T.2
Yan, R.T.3
Huynh, T.4
Gore, J.M.5
Montalescot, G.6
-
4
-
-
33645229796
-
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25,307 patients
-
Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27:519-526.
-
(2006)
Eur Heart J
, vol.27
, pp. 519-526
-
-
Andreotti, F.1
Testa, L.2
Biondi-Zoccai, G.G.3
Crea, F.4
-
5
-
-
79957598382
-
Combination warfarin-ASA therapy: Which patients should receive it, which patients should not, and why?
-
Douketis JD. Combination warfarin-ASA therapy: which patients should receive it, which patients should not, and why? Thromb Res 2011; 127:513-517.
-
(2011)
Thromb Res
, vol.127
, pp. 513-517
-
-
Douketis, J.D.1
-
6
-
-
71749093136
-
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes
-
Depta JP, Cannon CP, Fonarow GC, Zhao X, PeacockWF, Bhatt DL. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol 2009; 104:1171-1178.
-
(2009)
Am J Cardiol
, vol.104
, pp. 1171-1178
-
-
Depta, J.P.1
Cannon, C.P.2
Fonarow, G.C.3
Zhao, X.4
Peacock, W.F.5
Bhatt, D.L.6
-
7
-
-
31944437929
-
Aspirin, warfarin and a thienopyridine for acute coronary syndromes
-
DOI 10.1159/000089548
-
Konstantino Y, Iakobishvili Z, Porter A, Sandach A, Zahger D, Hod H, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006; 105:80-85. (Pubitemid 43189779)
-
(2006)
Cardiology
, vol.105
, Issue.2
, pp. 80-85
-
-
Konstantino, Y.1
Iakobishvili, Z.2
Porter, A.3
Sandach, A.4
Zahger, D.5
Hod, H.6
Hammerman, H.7
Gottlieb, S.8
Behar, S.9
Hasdai, D.10
-
8
-
-
80053177375
-
Consensus document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective
-
Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106:572-584.
-
(2011)
Thromb Haemost
, vol.106
, pp. 572-584
-
-
Faxon, D.P.1
Eikelboom, J.W.2
Berger, P.B.3
Holmes, D.R.4
Bhatt, D.L.5
Moliterno, D.J.6
-
9
-
-
77958138432
-
Atherothrombosis and atrial fibrillation: Important and often overlapping clinical syndromes
-
Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 2010; 104:657-663.
-
(2010)
Thromb Haemost
, vol.104
, pp. 657-663
-
-
Depta, J.P.1
Bhatt, D.L.2
-
10
-
-
80053336306
-
New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome
-
Davis EM, Packard KA, Knezevich JT, Campbell JA. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011; 31:975-1016.
-
(2011)
Pharmacotherapy
, vol.31
, pp. 975-1016
-
-
Davis, E.M.1
Packard, K.A.2
Knezevich, J.T.3
Campbell, J.A.4
-
12
-
-
77949534765
-
Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism
-
Yong CM, Boyle AJ. Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism. Curr Vasc Pharmacol 2010; 8:5-11.
-
(2010)
Curr Vasc Pharmacol
, vol.8
, pp. 5-11
-
-
Yong, C.M.1
Boyle, A.J.2
-
13
-
-
78650792758
-
Factor Xa and thrombin as targets for new oral anticoagulants
-
Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl 2):S5-S12.
-
(2011)
Thromb Res
, vol.127
, Issue.SUPPL. 2
-
-
Weitz, J.I.1
-
14
-
-
79957606320
-
The mechanism of action of rivaroxaban - An oral, direct Factor Xa inhibitor - Compared with other anticoagulants
-
Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res 2011; 127:497-504.
-
(2011)
Thromb Res
, vol.127
, pp. 497-504
-
-
Samama, M.M.1
-
15
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
-
Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
-
(2009)
Lancet
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
Burton, P.4
Poulter, R.5
Misselwitz, F.6
-
16
-
-
84862907587
-
Rivaroxaban in patients with a recent acute coronary syndrome
-
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.
-
(2012)
N Engl J Med
, vol.366
, pp. 9-19
-
-
Mega, J.L.1
Braunwald, E.2
Wiviott, S.D.3
Bassand, J.P.4
Bhatt, D.L.5
Bode, C.6
-
17
-
-
67649563209
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
-
Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
-
(2009)
Circulation
, vol.119
, pp. 2877-2885
-
-
Alexander, J.H.1
Becker, R.C.2
Bhatt, D.L.3
Cools, F.4
Crea, F.5
Dellborg, M.6
-
18
-
-
80052162121
-
Apixaban with antiplatelet therapy after acute coronary syndrome
-
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699-708.
-
(2011)
N Engl J Med
, vol.365
, pp. 699-708
-
-
Alexander, J.H.1
Lopes, R.D.2
James, S.3
Kilaru, R.4
He, Y.5
Mohan, P.6
-
19
-
-
80052232522
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial
-
Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781-2789.
-
(2011)
Eur Heart J
, vol.32
, pp. 2781-2789
-
-
Oldgren, J.1
Budaj, A.2
Granger, C.B.3
Khder, Y.4
Roberts, J.5
Siegbahn, A.6
-
20
-
-
84863142762
-
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial
-
Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012; 125:669-676.
-
(2012)
Circulation
, vol.125
, pp. 669-676
-
-
Hohnloser, S.H.1
Oldgren, J.2
Yang, S.3
Wallentin, L.4
Ezekowitz, M.5
Reilly, P.6
-
21
-
-
84857021520
-
Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized Controlled Trials
-
Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized Controlled Trials. Arch Intern Med 2012; 172:397-402.
-
(2012)
Arch Intern Med
, vol.172
, pp. 397-402
-
-
Uchino, K.1
Hernandez, A.V.2
-
22
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
-
(2011)
N Engl J Med
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
Pan, G.4
Singer, D.E.5
Hacke, W.6
-
23
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
-
(2011)
N Engl J Med
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
Lopes, R.D.4
Hylek, E.M.5
Hanna, M.6
-
25
-
-
79952301326
-
Apixaban in patients with atrial fibrillation
-
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
-
(2011)
N Engl J Med
, vol.364
, pp. 806-817
-
-
Connolly, S.J.1
Eikelboom, J.2
Joyner, C.3
Diener, H.C.4
Hart, R.5
Golitsyn, S.6
-
27
-
-
55349085390
-
The top 4 advances in antithrombotic care in the last year
-
Turpie AG. The top 4 advances in antithrombotic care in the last year. Thromb Res 2008; 123 (Suppl 1):S2-S6.
-
(2008)
Thromb Res
, vol.123
, Issue.SUPPL. 1
-
-
Turpie, A.G.1
-
28
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-115.
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-2115
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
-
29
-
-
79958126202
-
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial
-
Eikelboom JW,Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
-
(2011)
Circulation
, vol.123
, pp. 2363-2372
-
-
Eikelboom, J.W.1
Wallentin, L.2
Connolly, S.J.3
Ezekowitz, M.4
Healey, J.S.5
Oldgren, J.6
-
30
-
-
80053571188
-
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
-
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.
-
(2011)
Circulation
, vol.124
, pp. 1573-1579
-
-
Eerenberg, E.S.1
Kamphuisen, P.W.2
Sijpkens, M.K.3
Meijers, J.C.4
Buller, H.R.5
Levi, M.6
|